|
[2] 中国心血管健康与疾病报告编写组. 中国心血管健康与疾病报告2022概要 [J]. 中国循环杂志, 2023, 38(06): 583-612.DOI:10.3969/j.issn.1000-3614.2023.06.001. [3] DUFF S, MAFILIOS M S, BHOUNSULE P, et al. The burden of critical limb ischemia: a review of recent literature [J]. Vasc Health Risk Manag, 2019, 15: 187-208.DOI:10.2147/vhrm.S209241. [4] HöCKEL M, SCHLENGER K, DOCTROW S, et al. Therapeutic angiogenesis [J]. Arch Surg, 1993, 128(4): 423-9.DOI:10.1001/archsurg.1993.01420160061009. [5] TAKESHITA S, ZHENG L P, BROGI E, et al. Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model [J]. J Clin Invest, 1994, 93(2): 662-70.DOI:10.1172/jci117018. [6] ROBBINS J L, JONES W S, DUSCHA B D, et al. Relationship between leg muscle capillary density and peak hyperemic blood flow with endurance capacity in peripheral artery disease [J]. J Appl Physiol (1985), 2011, 111(1): 81-6.DOI:10.1152/japplphysiol.00141.2011. [7] ASKEW C D, GREEN S, WALKER P J, et al. Skeletal muscle phenotype is associated with exercise tolerance in patients with peripheral arterial disease [J]. J Vasc Surg, 2005, 41(5): 802-7.DOI:10.1016/j.jvs.2005.01.037. [8] ANNEX B H. Therapeutic angiogenesis for critical limb ischaemia [J]. Nat Rev Cardiol, 2013, 10(7): 387-96.DOI:10.1038/nrcardio.2013.70. [9] ANNEX B H, COOKE J P. New Directions in Therapeutic Angiogenesis and Arteriogenesis in Peripheral Arterial Disease [J]. Circ Res, 2021, 128(12): 1944-57.DOI:10.1161/circresaha.121.318266. [10] EMANUELI C, MADEDDU P. Therapeutic angiogenesis: translating experimental concepts to medically relevant goals [J]. Vascul Pharmacol, 2006, 45(5): 334-9.DOI:10.1016/j.vph.2006.08.012. [11] ISNER J M, PIECZEK A, SCHAINFELD R, et al. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb [J]. Lancet, 1996, 348(9024): 370-4.DOI:10.1016/s0140-6736(96)03361-2. [12] ARCONDéGUY T, LACAZETTE E, MILLEVOI S, et al. VEGF-A mRNA processing, stability and translation: a paradigm for intricate regulation of gene expression at the post-transcriptional level [J]. Nucleic Acids Res, 2013, 41(17): 7997-8010.DOI:10.1093/nar/gkt539. [13] GONG B, LIANG D, CHEW T G, et al. Characterization of the zebrafish vascular endothelial growth factor A gene: comparison with vegf-A genes in mammals and Fugu [J]. Biochim Biophys Acta, 2004, 1676(1): 33-40.DOI:10.1016/j.bbaexp.2003.10.006. [14] RAJAGOPALAN S, SHAH M, LUCIANO A, et al. Adenovirus-mediated gene transfer of VEGF(121) improves lower-extremity endothelial function and flow reserve [J]. Circulation, 2001, 104(7): 753-5.DOI:10.1161/hc3201.095192. [15] RAJAGOPALAN S, MOHLER E R, 3RD, LEDERMAN R J, et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication [J]. Circulation, 2003, 108(16): 1933-8.DOI:10.1161/01.Cir.0000093398.16124.29. [16] KUSUMANTO Y H, VAN WEEL V, MULDER N H, et al. Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: a double-blind randomized trial [J]. Hum Gene Ther, 2006, 17(6): 683-91.DOI:10.1089/hum.2006.17.683. [17] DEEV R V, BOZO I Y, MZHAVANADZE N D, et al. pCMV-vegf165 Intramuscular Gene Transfer is an Effective Method of Treatment for Patients With Chronic Lower Limb Ischemia [J]. J Cardiovasc Pharmacol Ther, 2015, 20(5): 473-82.DOI:10.1177/1074248415574336. [18] DEEV R, PLAKSA I, BOZO I, et al. Results of an International Postmarketing Surveillance Study of pl-VEGF165 Safety and Efficacy in 210 Patients with Peripheral Arterial Disease [J]. Am J Cardiovasc Drugs, 2017, 17(3): 235-42.DOI:10.1007/s40256-016-0210-3. [19] FORSTER R, LIEW A, BHATTACHARYA V, et al. Gene therapy for peripheral arterial disease [J]. Cochrane Database Syst Rev, 2018, 10(10): Cd012058.DOI:10.1002/14651858.CD012058.pub2. [20] NIKOL S, BAUMGARTNER I, VAN BELLE E, et al. Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia [J]. Mol Ther, 2008, 16(5): 972-8.DOI:10.1038/mt.2008.33. [21] BAUMGARTNER I, CHRONOS N, COMEROTA A, et al. Distribution and expression of FGF-1 transgene in lower limb muscle of individuals with severe PAOD. Circulation. 2004;110(suppl.):111-520. [22] BELCH J, HIATT W R, BAUMGARTNER I, et al. Effect of fibroblast growth factor NV1FGF on amputation and death: a randomised placebo-controlled trial of gene therapy in critical limb ischaemia [J]. Lancet, 2011, 377(9781): 1929-37.DOI:10.1016/s0140-6736(11)60394-2. |
